biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics trial registry — 15 ClinicalTrials.gov studies with program phase, status, and indication context.
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
Kyverna Therapeutics clinical trials
Registry index of 15 ClinicalTrials.gov studies linked to Kyverna Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Kyverna Therapeutics trial registry — 15 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Kyverna Therapeutics.
-
CCM-RNT-202402 — Phase 2
Clinical update -
KYV101-006 — Phase 3
Clinical update -
KYV101-007 — Phase 2
Clinical update -
KYV101-003 — Phase 2
Clinical update -
Standard of Care Treatment — Phase 3
Clinical update -
Standard lymphodepletion regimen — Phase 2
Clinical update -
KYV-101 — Phase 1
Clinical update -
KYV-101 (Biological) - 0.33 ×10^8 cells — Phase 1
Clinical update